P
Pavel Jansa
Researcher at First Faculty of Medicine, Charles University in Prague
Publications - 156
Citations - 8633
Pavel Jansa is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Pulmonary hypertension & Riociguat. The author has an hindex of 27, co-authored 140 publications receiving 7135 citations. Previous affiliations of Pavel Jansa include Charles University in Prague.
Papers
More filters
Journal ArticleDOI
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Tomás Pulido,Igor Adzerikho,Richard N. Channick,Marion Delcroix,Nazzareno Galiè,Hossein Ardeschir Ghofrani,Pavel Jansa,Zhi-Cheng Jing,Franck-Olivier Le Brun,Sanjay Mehta,Camilla Mittelholzer,Loïc Perchenet,B.K.S. Sastry,Olivier Sitbon,Rogério Souza,Adam Torbicki,Xiaofeng Zeng,Lewis J. Rubin,Gérald Simonneau +18 more
TL;DR: Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.
Journal ArticleDOI
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Hossein Ardeschir Ghofrani,Andrea Maria D'Armini,Friedrich Grimminger,Marius M. Hoeper,Pavel Jansa,Nick H. Kim,Eckhard Mayer,Gérald Simonneau,Martin R. Wilkins,Arno Fritsch,Dieter Neuser,Gerrit Weimann,Chen Wang +12 more
TL;DR: Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension.
Journal ArticleDOI
Chronic Thromboembolic Pulmonary Hypertension
Nick H. Kim,Marion Delcroix,David P. Jenkins,Richard N. Channick,Philippe Dartevelle,Pavel Jansa,Irene Lang,Michael M. Madani,Hitoshi Ogino,Vittorio Pengo,Eckhard Mayer +10 more
TL;DR: This report overviews and highlights these important interval developments as deliberated among the task force of CTEPH experts and presented at the 2013 World Symposium on Pulmonary Hypertension in Nice, France.
Journal ArticleDOI
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
Nazzareno Galiè,Lewis J. Rubin,Marius M. Hoeper,Pavel Jansa,Hikmet Al-Hiti,Gmb Meyer,Eleonora Chiossi,Andjela Kusic-Pajic,Gérald Simonneau +8 more
TL;DR: Bosentan treatment could be beneficial for patients with WHO FC II pulmonary arterial hypertension.
Journal ArticleDOI
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Results From an International Prospective Registry
Joanna Pepke-Zaba,Marion Delcroix,Irene Lang,Eckhard Mayer,Pavel Jansa,David Ambroz,Carmen M. Treacy,Andrea Maria D'Armini,Marco Morsolini,Repke J. Snijder,Paul Bresser,Adam Torbicki,Bent Bruun Kristensen,Jerzy Lewczuk,Iveta Simkova,Joan Albert Barberà,Marc de Perrot,Marius M. Hoeper,Sean Gaine,Rudolf Speich,Miguel Ángel Gómez-Sánchez,Gabor Kovacs,A. Hamid,Xavier Jaïs,Gérald Simonneau +24 more
TL;DR: Despite similarities in clinical presentation, operable and nonoperable CTEPH patients may have distinct associated medical conditions.